Invivyd (NASDAQ:IVVD) Shares Gap Up – Still a Buy?

Invivyd, Inc. (NASDAQ:IVVD)’s share price gapped up prior to trading on Monday . The stock had previously closed at $2.30, but opened at $2.42. Invivyd shares last traded at $2.5130, with a volume of 1,738,683 shares traded.

Wall Street Analyst Weigh In

Several equities research analysts have weighed in on IVVD shares. HC Wainwright increased their price objective on Invivyd from $5.00 to $10.00 and gave the stock a “buy” rating in a report on Friday, October 31st. D Boral Capital downgraded Invivyd from a “strong-buy” rating to a “hold” rating in a report on Tuesday, November 25th. BTIG Research assumed coverage on shares of Invivyd in a report on Monday. They issued a “buy” rating and a $10.00 price target on the stock. D. Boral Capital reaffirmed a “hold” rating on shares of Invivyd in a research report on Tuesday, November 25th. Finally, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Invivyd in a research note on Monday. Three equities research analysts have rated the stock with a Buy rating, three have given a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the stock presently has an average rating of “Hold” and a consensus price target of $8.00.

Invivyd Stock Down 2.0%

The company has a market cap of $639.91 million, a PE ratio of -5.84 and a beta of 0.61. The firm’s 50-day moving average is $2.14 and its 200-day moving average is $1.36.

Invivyd (NASDAQ:IVVD) last posted its quarterly earnings data on Thursday, November 6th. The company reported ($0.06) earnings per share for the quarter, missing the consensus estimate of ($0.05) by ($0.01). Invivyd had a negative net margin of 119.63% and a negative return on equity of 92.97%. The firm had revenue of $13.13 million for the quarter, compared to the consensus estimate of $12.00 million. As a group, equities research analysts anticipate that Invivyd, Inc. will post -1.64 EPS for the current fiscal year.

Insider Transactions at Invivyd

In other news, Director Kevin F. Mclaughlin acquired 50,000 shares of the stock in a transaction on Wednesday, November 19th. The stock was acquired at an average price of $2.50 per share, with a total value of $125,000.00. Following the completion of the transaction, the director owned 50,000 shares of the company’s stock, valued at $125,000. This represents a ∞ increase in their position. The purchase was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Company insiders own 25.40% of the company’s stock.

Institutional Investors Weigh In On Invivyd

Several hedge funds have recently bought and sold shares of the business. Catalyst Funds Management Pty Ltd bought a new stake in shares of Invivyd in the 2nd quarter worth approximately $27,000. Vanguard Personalized Indexing Management LLC boosted its holdings in Invivyd by 238.6% in the second quarter. Vanguard Personalized Indexing Management LLC now owns 39,941 shares of the company’s stock worth $29,000 after acquiring an additional 28,146 shares in the last quarter. Bank of America Corp DE grew its stake in shares of Invivyd by 330.5% in the third quarter. Bank of America Corp DE now owns 49,252 shares of the company’s stock worth $54,000 after acquiring an additional 37,811 shares during the last quarter. Jefferies Financial Group Inc. bought a new position in shares of Invivyd during the third quarter valued at $102,000. Finally, Bridgeway Capital Management LLC purchased a new position in shares of Invivyd in the 3rd quarter worth about $109,000. Institutional investors own 70.36% of the company’s stock.

Invivyd Company Profile

Invivyd, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company developed INVYMAB, a platform that combines viral surveillance and predictive modeling with advanced antibody engineering. Its pipeline includes PEMGRADA (pemivibart) injection, a half-life extended investigational monoclonal antibody (mAb) for the prevention of COVID-19 in adults and adolescents; VYD2311, an mAb candidate which is in preclinical studies for the prevention or treatment for COVID-19; and adintrvimab, that is in phase 3 clinical trials for the prevention or treatment of COVID-19.